The new era of adjuvant immunotherapy for patients with completely resected stage III/IV melanoma

Australie

$0

gratuit

RACGP CPD Program

1 heure

Oncology, Dermatology

2 Credits

This course is expired! Browse All Courses
APPRENDRE ENCORE PLUS

Description du cours

Australia has one of the highest rates of melanoma in the world and as a result, it is often referred to as ‘Australia’s national cancer’. Skin GPs and Dermatologists play an important role in identifying suspected melanoma and referring patients for assessment and treatment. In the new era of adjuvant immunotherapies for completely resected Stage III/IV melanoma, sentinel lymph node biopsy (SLNB) plays an important role in determining whether patients are eligible for therapy.

This 1-hour RACGP accredited activity aims to equip Skin GPs and Dermatologists with the information they need to assist oncologists in ensuring that eligible patients with completely resected Stage III/IV melanoma have access to adjuvant immunotherapy and are supported throughout their treatment.

It features two cases studies and expert video interviews from the multidisciplinary faculty.

This program is supported by an independent educational grant provided from Bristol Myers Squibb.

Détails du cours

Date d'expiration : 2022-12-31

Métiers: Médecin

Faculté

A/Prof Victoria Atkinson,
Medical Oncologist, Senior Staff Specialist, Princess Alexandra Hospital, QLD

Prof Andrew Barbour,
Senior General Surgeon, Greenslopes and Mater Private Hospitals, Princess Alexandra Hospital, QLD

Dr Lisa Beecham,
General Practitioner, Robina Town Medical Centre, QLD

Dr Dougal Coates,
Dermatologist, Clayfield Dermatology Specialist Centre, QLD

Accréditation

This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.

Activity no. 205436

Members are able to claim CPD activity points for 2 points through ‘Quick log’ on their RACGP CPD Dashboard.

Objectif(s) d'apprentissage

At the conclusion of this activity, participants will be able to:

  • Décrire the role of sentinel lymph node biopsy (SLNB) in identifying patients at high risk of recurrence or relapse following complete resection of melanoma, who may benefit from adjuvant immunotherapy
  • Recall the latest clinical evidence and recommendations on the role of adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma 
  • Incorporate into current practice a systematic approach for identifying patients with melanoma who should be referred to a surgeon for SLNB 
  • Outline the ways in which a multidisciplinary team approach can improve outcomes for patients with melanoma
This course is expired! Browse All Courses